Support CEPI
Join our coalition and help us create a future in which epidemics are no longer a threat to humanity.
Join our coalition and help us create a future in which epidemics are no longer a threat to humanity.
Lives were saved between 2010 and 2015 thanks to vaccines. (WHO, 2017)
The cost of the 2014 Ebola epidemic in west Africa. (C Huber et al, 2018)
The estimated annual global cost of moderately severe to severe pandemics (World Bank, 2017)
The average minimum cost for progressing one vaccine against each of WHO’s 11 priority epidemic infectious diseases. (D Gouglas et al, 2018)
CEPI was founded in Davos by the governments of Norway and India, the Bill & Melinda Gates Foundation, the Wellcome Trust, and the World Economic Forum.
To date, CEPI has secured financial support from Australia, Austria, Belgium, the Bill & Melinda Gates Foundation, Canada, Denmark, the European Commission, Finland, Germany, Hungary, Italy, Japan, Kuwait, Lithuania, Luxembourg, Malaysia, Mexico, Netherlands, New Zealand, Norway, Panama, Saudi Arabia, Serbia, Singapore, Switzerland, United Kingdom, USAID, Ethiopia, The Republic of Korea, Indonesia, and Wellcome.
Additionally, CEPI has also received support from private sector entities as well as public contributions through the UN Foundation COVID-19 Solidarity Response Fund.
Since our launch in 2017, CEPI has announced a number of calls for proposals to support the development of candidate vaccines against Middle East Respiratory Syndrome coronavirus (MERS-CoV), Nipah virus, Lassa virus, Rift Valley fever, and Chikungunya viruses, as well as rapid-response technologies to develop vaccines against Disease X. Most recently, we ran a funding call to develop and manufacture already proven vaccine technology that can be used against virus behind COVID-19.
To date, CEPI has committed to investing up to $480 million in 19 vaccine candidates against its priority pathogens (six against Lassa virus, five against MERS-CoV, four against Nipah virus, two against Chikungunya, two against Rift Valley fever) and three vaccine platforms to develop vaccines against Disease X.
With the rapid spread of COVID-19, CEPI has worked quickly and collaboratively with global health authorities and vaccine development partners. We have so far announced funding for nine programmes to rapidly develop vaccine candidates against COVID-19.
We create innovative partnerships between public, private, philanthropic, and civil organisations to develop vaccines against diseases with epidemic potential.
We invest in promising vaccine candidates against our priority pathogens and platform technologies that can enable rapid development of vaccines and immunoprophylactics against new and unknown pathogens. We also coordinate activities to improve our collective response to epidemics.
Learn more about our funding opportunities.
CEPI aims to invest in vaccine-based solutions that not only protect some of the most vulnerable people in the world but will also help to prevent future pandemics.
Get in touch to find out how your organisation could work with CEPI.